Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis

Table 1 Baseline characteristics of included studies comparing the prognosis of patients with ascites with that of patients without ascites

Ref.	Year	Patients’ origin	Study design	Study period	GC with PM	Previous treatment	No. of samples	mOS (mo)
							Ascites (+)/ascites (-)	Ascites (+)/ascites (-)
Sadeghi et al[16]	2000	France	PS	1995-1997	Yes	Chemotherapy, surgery	35/90	1.4/3.8
Chen et al[27]	2017	China	RS	2010-2014	Yes	Chemotherapy, surgery	207/311	9.87/14.27
Glehen et al[25]	2004	France	PS	1989-2000	Yes	Chemotherapy, surgery	17/32	5.0/15.6
Lan et al[21]	2010	China	RS	1993-2007	Yes	Surgery	24/67	7.3/10.1
Kitayama et al[22]	2012	Japan	PS	2004-2009	Yes	Chemotherapy, surgery	71/29	19.0/39.3
Peng et al[17]	2013	China	RS	1998-2011	Yes	Surgery	84/49	7.3/10.1
Shitara et al[15]	2013	Japan	RS	2005-2011	Yes	Chemotherapy, surgery	11/70	9.5/18.1
Nie et al[19]	2016	China	RS	2000-2014	Yes	Chemotherapy, surgery	313/347	-
Emoto et al[26]	2012	Japan	RS	2005-2010	Yes	Chemotherapy	73/29	-
Total							835/1024

Ascites (+): Patients with ascites; ascites (-): Patients without ascites; PS: Prospective study; RS: Retrospective study; GC: Gastric cancer; PM: Peritoneal metastasis.

Table 2 Baseline characteristics of included studies comparing the prognosis of patients with massive ascites with that of patients with mild to moderate ascites

Ref.	Year	Patients’ origin	Study design	Study period	GC with PM	Previous treatment	No. of samples	mOS (mo)
							Massive/Mild to moderate	Massive/Mild to moderate
Matsumoto et al[20]	2018	Japan	RS	2015-2016	Yes	Chemotherapy, surgery	14/26	3.9/9.6
Hara et al[24]	2017	Japan	RS	2006-2011	Yes	Chemotherapy	8/22	1.9/7.2
Shitara et al[15]	2013	Japan	RS	2005-2011	Yes	Chemotherapy, surgery	11/39	9.5/13.5
Total							33/87

Mild to moderate: Patients with mild to moderate ascites; Massive: Patients with massive ascites; RS: Retrospective study; GC: Gastric cancer; PM: Peritoneal metastasis.

Table 3 Baseline characteristics of included studies comparing the prognosis of patients with massive ascites with that of patients with no to moderate ascites

Ref.	Year	Patients’ origin	Study design	Study period	GC with PM	Previous treatment	No. of samples	mOS (mo)
							Massive/None-mod	Massive/None-mod
Ohnuma et al[18]	2018	Japan	RS	2004-2015	Yes	Chemotherapy	15/22	16.8/21.7
Ji et al[23]	2018	China	RS	2005-2017	Yes	Chemotherapy, surgery	33/77	9.0/16.6
Iwasa et al[4]	2010	Japan	RS	1999-2006	Yes	Chemotherapy	21/58	-
Total							69/157

None–mod: Patients with none to moderate ascites; Massive: Patients with massive ascites; RS: Retrospective study; GC: Gastric cancer; PM: Peritoneal metastasis.

Table 4 Quality of included studies

Ref.	Selection of subjects (score)	Intergroup comparability (score)	Result measurement (score)	NOS
Sadeghi et al[16]	4	1	3	8
Chen et al[27]	3	1	3	7
Glehen et al[25]	4	1	3	8
Lan et al[21]	3	1	3	7
Kitayama et al[22]	4	1	3	8
Peng et al[17]	3	1	3	7
Shitara et al[15]	3	1	3	7
Nie et al[19]	3	1	3	7
Ohnuma et al[18]	3	1	3	7
Matsumoto et al[20]	3	1	3	7
Hara et al[24]	3	1	3	7
Ji et al[23]	3	1	3	7
Iwasa et al[4]	3	1	3	7
Emoto et al[26]	3	1	3	7

NOS: The Newcastle-Ottawa Scale.